Atika Capital Management LLC Bluebird Bio, Inc. Transaction History

Atika Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $1.07 Million - $1.69 Million	-18,100 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $35,544 - $46,996	-400 Reduced 2.16%	18,100 $2.64 Million
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $548,020 - $701,745	-5,500 Reduced 22.92%	18,500 $2.9 Million
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $264,500 - $377,350	-2,500 Reduced 9.43%	24,000 $4.1 Million
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $1.5 Million - $2.42 Million	18,500 Added 231.25%	26,500 $4.72 Million
Q3 2017 Nov 14, 2017	SELL	$57.74 - $91.42 $981,580 - $1.55 Million	-17,000 Reduced 68.0%	8,000 $1.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	25,000	25,000 $2.63 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.